David Lalka

2.2k total citations
71 papers, 1.8k citations indexed

About

David Lalka is a scholar working on Pharmacology, Molecular Biology and Pharmacology. According to data from OpenAlex, David Lalka has authored 71 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pharmacology, 16 papers in Molecular Biology and 15 papers in Pharmacology. Recurrent topics in David Lalka's work include Pharmacogenetics and Drug Metabolism (18 papers), Analytical Methods in Pharmaceuticals (11 papers) and Antibiotics Pharmacokinetics and Efficacy (9 papers). David Lalka is often cited by papers focused on Pharmacogenetics and Drug Metabolism (18 papers), Analytical Methods in Pharmaceuticals (11 papers) and Antibiotics Pharmacokinetics and Efficacy (9 papers). David Lalka collaborates with scholars based in United States, Canada and Spain. David Lalka's co-authors include Craig K. Svensson, David J. Edwards, Richard L. Slaughter, Allan J. McLean, James G. Baxter, Patrick J. McNamara, M.B. Meyer, Milford G. Wyman, M. Gibaldi and Milo Gibaldi and has published in prestigious journals such as Journal of the American College of Cardiology, The American Journal of Cardiology and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

David Lalka

70 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Lalka United States 23 364 341 339 267 257 71 1.8k
B. Whiting United Kingdom 28 492 1.4× 294 0.9× 243 0.7× 303 1.1× 460 1.8× 100 2.3k
B Beermann Sweden 27 388 1.1× 358 1.0× 403 1.2× 561 2.1× 380 1.5× 98 2.4k
Kenneth M. Piafsky Canada 15 413 1.1× 351 1.0× 385 1.1× 145 0.5× 369 1.4× 18 1.7k
Peter J. Meffin United States 22 231 0.6× 309 0.9× 194 0.6× 249 0.9× 136 0.5× 34 1.3k
M. J. Kendall United Kingdom 29 401 1.1× 300 0.9× 214 0.6× 497 1.9× 407 1.6× 127 2.4k
Renato L. Galeazzi Switzerland 16 371 1.0× 243 0.7× 280 0.8× 177 0.7× 249 1.0× 45 1.6k
Mario L. Rocci United States 24 360 1.0× 466 1.4× 326 1.0× 197 0.7× 322 1.3× 73 2.1k
Robert A. Upton United States 27 675 1.9× 425 1.2× 339 1.0× 164 0.6× 361 1.4× 62 2.2k
Samuel Vožeh Switzerland 18 403 1.1× 251 0.7× 291 0.9× 248 0.9× 300 1.2× 28 1.8k
Marc G. Bogaert Belgium 21 282 0.8× 198 0.6× 243 0.7× 191 0.7× 145 0.6× 85 1.5k

Countries citing papers authored by David Lalka

Since Specialization
Citations

This map shows the geographic impact of David Lalka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Lalka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Lalka more than expected).

Fields of papers citing papers by David Lalka

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Lalka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Lalka. The network helps show where David Lalka may publish in the future.

Co-authorship network of co-authors of David Lalka

This figure shows the co-authorship network connecting the top 25 collaborators of David Lalka. A scholar is included among the top collaborators of David Lalka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Lalka. David Lalka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gutierrez, Gloria E., David Lalka, I. Ross Garrett, G. Rossini, & Gregory R. Mundy. (2006). Transdermal application of lovastatin to rats causes profound increases in bone formation and plasma concentrations. Osteoporosis International. 17(7). 1033–1042. 80 indexed citations
2.
Slain, Douglas, et al.. (2005). Effect of High‐Dose Vitamin C on the Steady‐State Pharmacokinetics of the Protease Inhibitor Indinavir in Healthy Volunteers. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 25(2). 165–170. 35 indexed citations
3.
Kovács, Péter, et al.. (1999). High-Dose Omeprazole: Use of a Multiple-Dose Study Design to Assess Bioequivalence and Accuracy of CYP2C19 Phenotyping. Therapeutic Drug Monitoring. 21(5). 526–526. 5 indexed citations
4.
Weber, Cornelia, K. Stoeckel, & David Lalka. (1994). Accumulation Kinetics of Propranolol in the Rat: Comparison of Michaelis– Menten-Mediated Clearance and Clearance Changes Consistent with the “Altered Enzyme Hypothesis”. Pharmaceutical Research. 11(3). 420–425. 2 indexed citations
5.
Lalka, David, et al.. (1993). The Hepatic First‐Pass Metabolism of Problematic Drugs. The Journal of Clinical Pharmacology. 33(7). 657–669. 20 indexed citations
6.
Lalka, David, et al.. (1993). Pharmacokinetics of D‐propranolol following oral, intra‐arterial and intraportal administration: Contrasting effects of oral glucose pretreatment. Biopharmaceutics & Drug Disposition. 14(3). 217–231. 4 indexed citations
7.
Baxter, James G., et al.. (1992). Pharmacokinetic and metabolic aspects of the moclobemide-food interaction. Psychopharmacology. 106(S1). S37–S39. 3 indexed citations
8.
Lalka, David, et al.. (1988). Influence of food on the presystemic metabolism of drugs. Pharmacology & Therapeutics. 38(2). 253–267. 32 indexed citations
9.
Lalka, David, et al.. (1988). Reversed-phase high-performance liquid chromatographic assay to quantitate diastereomeric derivatives of metoprolol enantiomers in plasma. Journal of Chromatography B Biomedical Sciences and Applications. 433. 318–325. 25 indexed citations
10.
Modi, Marlene, James M. Hassett, & David Lalka. (1988). Influence of posture on hepatic perfusion and the presystemic biotransformation of propranolol: simulation of the food effect. Clinical Pharmacology & Therapeutics. 44(3). 268–274. 15 indexed citations
11.
Svensson, Craig K., et al.. (1986). Free Drug Concentration Monitoring in Clinical Practice. Clinical Pharmacokinetics. 11(6). 450–469. 152 indexed citations
12.
Svensson, Craig K., et al.. (1985). Effects of hydralazine, nitroglycerin, and food on estimated hepatic blood flow. Clinical Pharmacology & Therapeutics. 37(4). 464–468. 16 indexed citations
13.
Edwards, David J., et al.. (1984). Factors Affecting Quinidine Protein Binding in Humans. Journal of Pharmaceutical Sciences. 73(9). 1264–1267. 27 indexed citations
14.
Kung, Mei‐Ping, Yau‐Kwan Ho, David Lalka, & Thomas J. Bardos. (1984). Plasma clearance and tissue distribution of partially thiolated polycytidylic acid and its degradation products in rodents.. PubMed. 44(10). 4602–6. 4 indexed citations
15.
Edwards, David J., et al.. (1984). Factors Affecting Quinidine Protein Binding in Man. Clinical Pharmacokinetics. 9(Supplement 1). 96–97. 5 indexed citations
16.
17.
Pieper, John A., et al.. (1981). Effect of food on lidocaine kinetics: Mechanism of food-related alteration in high intrinsic clearance drug elimination. Clinical Pharmacology & Therapeutics. 30(4). 455–460. 30 indexed citations
18.
McNamara, Patrick J., et al.. (1980). Effect of smoking on binding of lidocaine to human serum proteins. Journal of Pharmaceutical Sciences. 69(6). 749–751. 17 indexed citations
19.
Souich, Patrick du, et al.. (1978). Comparison of screening methods for determination of N4-acetyltransferase capacity (acetylator phenotype) in outbred rabbit strains.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 92(2). 290–6. 1 indexed citations
20.
Lalka, David & Hal S. Feldman. (1974). Absolute Drug Bioavailability: Approximation without Comparison to Parenteral Dose for Compounds Exhibiting Perturbable Renal Clearance. Journal of Pharmaceutical Sciences. 63(11). 1812–1812. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B. Whiting Breakdown of academic impact, for papers by B Beermann Breakdown of academic impact, for papers by Kenneth M. Piafsky Breakdown of academic impact, for papers by Peter J. Meffin Breakdown of academic impact, for papers by M. J. Kendall Breakdown of academic impact, for papers by Renato L. Galeazzi Breakdown of academic impact, for papers by Mario L. Rocci Breakdown of academic impact, for papers by Robert A. Upton Breakdown of academic impact, for papers by Samuel Vožeh Breakdown of academic impact, for papers by Marc G. Bogaert
Rankless by CCL
2026